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Abstract
 
Microbial pathogens have been selected for the capacity to evade or manipulate host responses
 
in order to survive after infection. Chlamydia,
 
 
 
an obligate intracellular pathogen and the caus-
ative agent for many human diseases, can escape T lymphocyte immune recognition by degrad-
ing host transcription factors required for major histocompatibility complex (MHC) antigen
expression. We have now identified a chlamydial protease– or proteasome–like activity factor
(CPAF) that is secreted into the host cell cytosol and that is both necessary and sufficient for the
degradation of host transcription factors RFX5 and upstream stimulation factor 1 (USF-1). The
CPAF gene is highly conserved among chlamydial strains, but has no significant overall homol-
ogy with other known genes. Thus, CPAF represents a unique secreted protein produced by an
obligate intracellular bacterial pathogen to interfere with effective host adaptive immunity.
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Introduction
 
Chlamydia has to replicate within a cytoplasmic vacuole
of eukaryotic cells and has adapted so well that it can per-
sist in its host for a long period of time. Although chla-
mydial infection is known to be responsible for many se-
vere human diseases ranging from trachoma after ocular
infections to life-threatening complications after urogeni-
tal infections, the mechanism of chlamydial pathogenesis
is still not clear. It is thought that the persistent infection is
a major cause of chlamydia-induced diseases in humans (1,
 
2). Chlamydia-infected cells are able to continuously
release inflammatory cytokines (3). Unfortunately, the
tissue-damaging inflammatory responses induced by
chlamydial infection often fail to efficiently eliminate the
chlamydial organisms that are hidden inside the persis-
tently infected host cells. We have hypothesized that
chlamydia may have evolved strategies for evading host
defense mechanisms in order to establish and to maintain a
persistent infection.
 
Multicellular organisms have evolved various responses
for controlling microbial infections, which, in turn, select
for microbial pathogens with the ability to evade these same
host defenses. Our previous studies have shown that
chlamydia possesses varied strategies for interfering with or
preventing both immune recognition and immune effector
activity (4–6). Chlamydial infection suppressed both MHC
class I and class II antigen expression in the infected cells.
The inhibition of MHC antigen expression was correlated
with the degradation of host transcription factors RFX5 and
 
upstream stimulation factor 1 (USF-1).
 
1
 
 Furthermore, deg-
radation of both RFX5 and USF-1 was caused by a
chlamydial protease– or proteasome–like activity (CPA) in
the cytosol of chlamydia-infected cells and the CPA was in-
hibited only by an irreversible proteasomal inhibitor lacta-
cystin among all the inhibitors tested (4, 5). A logical exten-
sion of these previous studies is to identify the factor(s)
responsible for the chlamydial proteasome-like activity,
which is the focus of this study. Using a column chroma-
tography approach, we have purified a chlamydial protein
that correlates with the CPA. We designated this chlamyd-
ial protein as CPA factor (CPAF).
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Abbreviations used in this paper:
 
 CPA, chlamydial protease– or protea-
some–like activity; CPAF, CPA factor; GST, glutathione 
 
S
 
-transferase;
MOMP, chlamydial major outer membrane protein; NE, nuclear extract;
ORF, open reading frame; USF, upstream stimulation factor. 
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Materials and Methods
 
Column Chromatography.
 
For purification and sequence iden-
tification of CPAF, cytosolic protein preparation from 
 
z
 
200
large flasks (150 cm
 
2
 
) of chlamydia-infected HeLa cells (HeLa L2
S100; reference 6) was subjected to the following three consecu-
tive column separations: DEAE, heparin, and Mono Q (all col-
umns were from Amersham Pharmacia Biotech). An AKTA pu-
rifier 10 (Amersham Pharmacia Biotech) was used to run the
columns. Fractions collected from each column were monitored
for both degradation activity in a cell-free assay as we have estab-
lished previously (4), and total protein profiles on SDS-polyacryl-
amide gels. Fractions with degradation activity were pooled and
both the protein concentration and degradation activity of the
pooled fractions were carefully titrated. These measurements
were used to calculate the purification efficiency. The pooled
fractions were loaded to the next column for further fraction-
ation. However, the pooled fractions collected from DEAE col-
umn were diluted 1:2 with H
 
2
 
O to reduce the salt concentration
before the heparin column purification. Two dominant protein
bands that correlated with the degradation activity from the final
Mono Q column were excised for protein sequence identifica-
tion using both mass spectrometry analysis (Biorealis Biosciences
Inc.) and NH
 
2
 
-terminal sequence determination (University of
Victoria, British Columbia, Canada). For chromatographic analy-
sis of CPA, a size exclusion column was loaded with HeLa L2
S100 and eluted with PBS as we described previously (4). The
eluted fractions were subjected to both the RFX5 degradation
activity measurement and Western blot detection of host 20S
proteasome and CPAF components.
 
Western Blot.
 
The Western blot assay was carried out as
we described previously (7). Mouse antibodies were used to
detect the NH
 
2
 
-terminal portion of CPAF (CPAFn) fragment
(CPAFn54b; mIgG1; data not shown), chlamydial major outer
membrane protein (MOMP) (MC22; mIgG3; data not shown),
eukaryotic HSP70 (IgG2a; Santa Cruz Biotechnology, Inc.), and
20S proteasome subunits (AFFINITI Research Products Lim-
ited). Rabbit antibodies were used to detect RFX5 (Rockland
Immunochemicals), USF-1, and USF-2 (Santa Cruz Biotechnol-
ogy, Inc.).
 
Cell-free Degradation Assay.
 
The cell-free degradation assay
was performed as described previously (4). To generate fusion
proteins for the cell-free assay, chlamydial DNA sequences cod-
ing for CPAF or CPAF fragments were cloned into a pGEX vec-
tor (Amersham Pharmacia Biotech) and expressed as fusion pro-
teins with the glutathione 
 
S
 
-transferase (GST) as fusion partner.
The fusion proteins were purified with glutathione-conjugated
agarose beads as described in the manufacturer’s manual (Amer-
sham Pharmacia Biotech). The following procedure was used to
prepare nuclear extracts (NEs) as substrate (containing RFX5 and
USF-1 and USF-2) for the cell-free assay. Normal HeLa cells
were dounced to break cytoplasmic membranes and the pellets
were repeatedly washed with a buffer consisting of 1% NP-40
and 150 mM NaCl in 50 mM Tris, pH 8.0, plus a protease inhib-
itor cocktail to remove cytosol/membrane proteins as much as
possible. The final washed nuclear pellets were extracted with a
buffer consisting of 0.5 M NaCl and 1% Triton X-100 in 20 mM
Tris, pH 8.0. The NEs thus prepared are essentially free of 20S
proteasome components as detected on Western blot (data not
shown). The human RFX5 gene from pREP-4/RFX5 plasmid
(provided by Dr. P.J. van den Elsen, Leiden University Medical
Center, Leiden, The Netherlands) was cloned into the pGEX
vector and RFX5 was expressed in the JM109 
 
Escherichia coli
 
strain as a GST fusion protein. The GST-RFX5 fusion protein
 
was purified to homogeneity using glutathione-conjugated aga-
rose beads as described above. The purified GST-RFX5 was used
as substrate in the cell-free degradation assays.
 
Immunofluorescence Staining Assay.
 
Immunofluorescence de-
tection of CPAF in chlamydia-infected cells was carried out as
described previously (6, 7). In brief, HeLa cell monolayer was in-
fected with 
 
Chlamydia trachomatis
 
 L2 for 30 h. The monolayer, af-
ter it was fixed with paraformaldehyde (Sigma-Aldrich) and per-
meabilized with Saponin (Sigma-Aldrich), was costained with
Hoechst 32258 (blue), anti-MOMP antibody MC22 (probed
with an FITC-conjugated, mouse IgG3-specific secondary anti-
body), and anti-CPAFn antibody 54b (probed with a Cy3-conju-
gated, mouse IgG1-specific secondary antibody). Images were ac-
quired individually for each stain in gray using a Cooker digital
camera connected to an AX70 Olympus microscope, and the sin-
gle-color images were merged in frame into the triple-color im-
age using the software Image Pro.
 
Immunoprecipitation Assay.
 
The immunoprecipitation assays
were carried out as described previously (4, 8). For antibody de-
pletion of CPAF and the MOMP, both the anti-CPAFn and
anti-MOMP antibodies were used to precipitate proteins in ly-
sates of chlamydia-infected HeLa cells without radiolabeling (4).
The intact lysate, the supernatant after antibody precipitation, and
the proteins precipitated by the antibodies were all examined for
their ability to degrade RFX5 in a cell-free assay. To visualize the
proteins precipitated by the above antibodies, a radioimmunopre-
cipitation assay was performed (8). In brief, HeLa cells infected
with chlamydia were metabolically labeled with [S
 
35
 
]methionine/
cysteine (ICN Biomedicals) and the proteins in the labeled cell
lysate were precipitated with the corresponding antibodies. The
supernatant after the first precipitation (I
 
8
 
) was subjected to a sec-
ond immunoprecipitation (II
 
8
 
) with the same antibodies. Both
the anti-CPAFn and anti-MOMP antibodies completely re-
moved the corresponding molecules from the lysates during I
 
8
 
precipitation.
 
Results
 
Purification and Sequence Identification of CPAF.
 
A
chlamydial protease–like activity (designated as CPA) has
been detected in the cytosol of chlamydia-infected cells
and its presence correlated with degradation of host tran-
scription factors (4). To better understand the molecular
mechanisms underlying chlamydial evasion of host im-
mune recognition, we used a column chromatography ap-
proach to identify the factor(s) responsible for CPA (Fig. 1
A). Although it was not possible to correlate any obvious
protein bands with degradation activity in fractions eluted
from either DEAE or heparin column, these two purifica-
tion steps allowed us to remove most of the unwanted
proteins and to dramatically enrich the degradation activity
(Table I). The final Mono Q column purification resulted
in 
 
z
 
1,000-fold increase in specific activity (Table I). In-
deed, two predominant protein bands in fractions eluted
from a final step Mono Q column correlated with the nu-
clear protein degradation activity (Fig. 1 A). Both protein
bands were excised for sequence identification using mass
spectrometry (Fig. 1 B). The sequences of a total of eight
tryptic fragments derived from the bottom band matched 
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the sequence of the NH
 
2
 
-terminal portion of a chlamydial
protein encoded by open reading frame (ORF) CT858
(sequence data are available from GenBank/EMBL/DDBJ
under accession no. AE001359; http://violet.berkeley.
edu:4231/ident.html; reference 9), whereas the sequences
of 17 tryptic fragments from the top band matched the
sequence of the COOH-terminal portion of the same
chlamydial protein (Fig. 1 B). These observations indicate
that the two purified protein bands are encoded by a single
ORF in the chlamydial genome. We have thus designated
the bottom band protein as CPAFn and the top as CPAFc
(Fig. 1). The sequence identity of CPAF was further
 
confirmed using conventional NH
 
2
 
-terminal sequenc-
ing (data not shown). The CPAF gene has no signifi-
cant overall homology to any other known genes despite
its high conservation among chlamydial strains (9–11;
data not shown). Although a short CPAF sequence
(
 
488
 
PICVLINEQDFSCADFFPVVLKDNDRALIVGTRT
AGAG
 
525
 
) was found to share a significant homology with
the COOH-terminal sequences of tail-specific proteinases
from various species (data not shown), the function of the
conserved sequence domain is not yet known. Because of
the limited homology, the CPAF gene was designated as
either hypothetical ORF or “predicted protease contain-
Figure 1. Purification and sequence identification of
CPAF. (A) A cytosolic protein preparation from chla-
mydia-infected HeLa cells (HeLa L2 S100) was subjected
to three consecutive column separations as listed in the fig-
ure. Fractions collected from each column were monitored
for both degradation activity in a cell-free assay and total
protein profiles on SDS-polyacrylamide gels. Fractions
with degradation activity were pooled and loaded to the
next column for further fractionation. Two dominant pro-
tein bands that correlated with the degradation activity
from the final Mono Q column were excised for protein
sequence identification. “1” indicates partial digestion of
the substrate and “11” indicates complete loss of sub-
strate. “2” indicates that the substrate band is intact com-
pared with the substrate alone sample. (B) List of tryptic
peptides that match the chlamydial ORF CT858-encoded
protein (sequence data are available from http://www.
ncbi.nlm.nih.gov/Entrez/protein.html under accession no.
A71461). Amino acid residues are represented using the
single letter codes and numbered according to their posi-
tions in CPAF sequence. Tryptic fragments derived from
the top band match the COOH-terminal portion whereas
those from the bottom band match the NH2-terminal por-
tion of CPAF. The top band was designated as CPAFc and
the bottom band as CPAFn. 
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ing interphotoreceptor retinoid-binding protein (IRBP)
and 13,14-dihydroxy-retinol (DHR) domains” (http://
violet.berkeley.edu:4231/ident.html; references 9–11).
 
CPAF Is Both Necessary and Sufficient for Degradation of
Host Transcription Factors.
 
We have previously demon-
strated that the chlamydial proteasome–like activity does
not reflect the function of host proteasome components (4).
When fractions obtained from a size exclusion chromatog-
raphy column were probed with an antibody recognizing
CPAFn, the chlamydial proteasome–like activity measured
with RFX5 degradation was found to correlate very well
with the presence of the CPAFn fragment but not host pro-
teasome components (Fig. 2 A). To test whether CPAF is
necessary for the chlamydial proteasome–like activity, we
used the anti-CPAFn antibody to precipitate CPAFn from
chlamydia-infected HeLa cell lysate and measured the
RFX5 degradation activity of the precipitated pellets as well
as the activity of the supernatants after the antibody deple-
tion (Fig. 2 B). The total lysate of chlamydia-infected HeLa
cells efficiently degraded RFX5. However, the supernatants
remaining after antibody-mediated depletion of CPAFn
completely lost the ability to degrade RFX5, whereas
RFX5 degradation activity was readily detected in the pre-
cipitated material. Depletion of RFX5 degradation activity
by anti-CPAFn was specific, because a control antibody
 
recognizing the MOMP failed to precipitate this activity
from the lysates. To monitor the efficiency of the antibody
precipitation, radiolabeled lysate from chlamydia-infected
HeLa cells was similarly precipitated with anti-CPAFn (I
 
8
 
precipitation) and the supernatant after the first precipita-
tion was reprecipitated (II
 
8
 
 precipitation) with the same re-
agent (Fig. 2 C). Autoradiography after SDS-PAGE of the
material in both the I
 
8
 
 and II
 
8
 
 immunoprecipitates revealed
that the anti-CPAFn antibody effectively removed both the
CPAFn and CPAFc fragments from the lysates during the I
 
8
 
precipitation, because the II
 
8
 
 immunoprecipitate showed
minimal amounts of CPAF fragments. The control anti-
MOMP antibody efficiently precipitated MOMP but not
CPAF molecules from the lysates (Fig. 2 C). Together,
these experiments demonstrate that CPAF or CPAF-associ-
ated material is necessary for RFX5 degradation activity in
chlamydia-infected cell lysates.
To evaluate whether CPAF is sufficient for degrading
host transcription factors, the protein encoded by the full-
length CPAF gene was expressed as a fusion with GST, us-
ing a bacterial system. The purified GST-CPAF was evalu-
ated for its ability to degrade RFX5 in a cell-free assay in
comparison to material extracted from infected cells (HeLa
L2 S100; Fig. 2 D). The HeLa L2 S100 degraded both the
RFX5 and USF-1 transcription factors in NEs, whereas the
material from uninfected HeLa cells (HeLa S100) failed to
do so. Furthermore, even though the chlamydia proteolytic
activity could be fractionated away from host cell 20S pro-
teasomes (Fig. 2 A), the degradation activity of the HeLa
L2 S100 was completely inhibited by lactacystin, an irre-
versible inhibitor of proteasomal proteases. These observa-
tions suggest that a chlamydial proteasome–like activity was
being measured in this assay, as reported previously (4).
More significantly, the purified GST-CPAF was able to de-
grade both RFX5 and USF-1 and the degradation was in-
hibitable by lactacystin. A GST fusion protein containing
only the COOH-terminal portion of CPAF (GST-CPAFc)
failed to degrade either of the host nuclear proteins even at
a concentration 20 times higher than that of GST-CPAF
(Fig. 2 D). These observations demonstrated that the puri-
fied CPAF is sufficient to mediate the degradation of host
transcription factors in HeLa cell NEs. However, this set of
experiments failed to address whether other components in
the NEs also contributed to the degradation activity.
To further confirm that CPAF alone is sufficient for the
degradation activity, we expressed the human transcription
factor RFX5 in a prokaryotic system as a GST fusion pro-
tein. The GST-RFX5 was purified to homogeneity (Fig. 2
E) and the purified protein was used as the substrate for
measuring the degradation activity of the cloned CPAF in a
cell-free assay (Fig. 2 F). The cloned CPAF completely de-
graded the endogenous RFX5 in HeLa cell NEs and the
degradation activity was inhibited by lactacystin, which is
consistent with the observations described above in Fig. 2
D. More importantly, the cloned CPAF also effectively de-
 
Table I.
 
Summary of CPAF Purification
 
Purification
step Volume
 
*
 
Total
protein
Estimated
CPAF
activity
 
‡
 
Estimated
total
CPAF
activity
Estimated
activity
recovery
 
§
 
Estimated
activity
enrichment
 
i
 
ml mg hdf/mg hdf % fold
 
L2 S100 100 5,310 0.094 499 100 1
DEAE 70 214 0.97 208 42 10
Heparin 150 13 11.49 149 30 122
Mono Q 5 0.5 90 45 9 957
 
To monitor the purification efficiency, the pooled fractions from each
column purification were titrated for determining both protein
concentration and degradation activity. The activity was measured by
serial dilution of the pooled fractions and expressed as the highest
dilution factors per mg of protein, under which the degradation activity
was still detectable. These measurements were further used for
calculating the recovery and enrichment of CPAF activity.
 
*
 
Final volumes of pooled fractions as indicated in Fig. 1 A (prior to di-
lution).
 
‡
 
CPAF activity was estimated based on the highest dilution of the
pooled fractions when the CPAF degradation activity was still detect-
able and expressed as the highest dilution factors per mg of protein. hdf,
highest dilution factors.
 
§
 
The recovery of CPAF activity was calculated based on the total activ-
ity recovered after each purification step using the total activity in L2
S100 as 100%.
 
i
 
The enrichment was calculated based on CPAF activity per mg of pro-
tein (as described for Estimated CPAF activity above) using the activity
in L2 S100 as the base. 
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Figure 2. CPAF is both necessary and sufficient for degradation of host transcription factors. (A) HeLa L2 S100 was subjected to Superdex 200 size ex-
clusion column analysis as described previously (4). The fractions were assayed for both RFX5 degradation activity and the presence of either host 20S
proteasome subunits or CPAFn fragment. The presence of CPAFn but not host 20S proteasomes correlated with RFX5 degradation activity. (B) The ef-
fect of antibody depletion of CPAF on RFX5 degradation activity in chlamydia-infected HeLa cell lysates. Both the anti-CPAFn (54b) and anti-MOMP
(MC22) antibodies were used to precipitate proteins from chlamydia-infected HeLa cell lysate. The intact (total) lysate, the supernatant after antibody
precipitation, and the proteins precipitated by the antibodies (pellet) were all examined for their ability to degrade RFX5 in a cell-free assay. The anti-
CPAFn antibody precipitated RFX5 degradation activity from supernatants to pellets. (C) Radioimmunoprecipitation analysis of proteins precipitated by
anti-CPAFn or anti-MOMP antibodies. HeLa cells infected with chlamydia were metabolically labeled and the proteins in the labeled cell lysate were
precipitated with antibodies. The supernatant after the first precipitation (I8) was subjected to a second immunoprecipitation (II8) with the same antibod-
ies. Both the anti-CPAFn and anti-MOMP antibodies completely removed the corresponding molecules from the lysates during I8 precipitation. The ra-
tio of cell lysate vs. antibody was the same as in Fig. 2 B. (D) Degradation of transcription factors RFX5 and USF-1 by chlamydia-synthesized and bacte-
rium-expressed CPAF in a cell-free assay with or without the inhibitor lactacystin. HeLa L2 S100 (containing chlamydia-synthesized CPAF) was used as
positive control, and HeLa S100 was used as a negative control. Bacterium-expressed GST-CPAF was used at a final concentration of either 0.2 (low;
sufficient for RFX5 degradation) or 0.6 mM (high; sufficient for both RFX5 and USF-1 degradation). The degradation was inhibitable by the protea-
some inhibitor lactacystin (100 mM). A fusion protein containing GST and the COOH-terminal portion of CPAF (GST-CPAFc) failed to degrade any
of the nuclear factors even at 4 mM. The anti–USF-2 antibody can detect both USF-1 and USF-2 as described previously (reference 4). Ns, nonspecific
binding. (E). Purification of the recombinant human RFX5 from a bacterial expression system. The GST-RFX5 fusion protein was purified with glu-
tathione-agarose beads as described in Materials and Methods. Different amounts of the purified protein were loaded to a 12% polyacrylamide SDS gel.
After electrophoresis, the gel was stained with Coomassie blue dye. The GST-RFX5 fusion protein has a MW of z100 kD. (F). Degradation of the pu-
rified human recombinant RFX5 by CPAF in a cell-free assay. The cell-free assay was carried out in the exact same way as described in D, except that
0.5 mg of the purified GST-RFX5 instead of the NEs was used as substrate in some reactions as indicated in the figure. The digestion experiment with
the purified GST-RFX5 as substrate was repeated four times and similar results were observed. RFX5 in NEs is defined as endogenous and the bacte-
rium-expressed GST-RFX5 fusion protein defined as recombinant. 
940
 
Chlamydial Secretion of a Protease-like Activity Factor
 
graded the recombinant human RFX5 purified from a bac-
terial expression system (Fig. 2 F). Degradation of the re-
combinant RFX5 was inhibited by lactacystin, suggesting
that the same enzymatic activity was responsible for the
degradation of both endogenous and recombinant RFX5.
A similarly purified control GST-CPAFc fusion protein
failed to degrade the recombinant RFX5, suggesting that
degradation of RFX5 measured in the assay was not con-
tributed by bacterial contaminants (if there was any) or the
GST fusion partner. These observations clearly demon-
strate that the chlamydial CPAF alone is sufficient for de-
grading host RFX5.
 
Intracellular Distribution of CPAF during Chlamydial Infec-
tion.
 
Although CPAF is encoded by the chlamydial ge-
nome, the host transcription factor degradation activity was
detected in the cytosol of the infected cells (4), suggesting
that CPAF is secreted into host cell cytosol. We next used
cell fractionation followed by immunoblotting to further
evaluate the subcellular distribution of CPAF during
chlamydial infection (Fig. 3 A). The majority of RFX5
degradation activity was associated with the cytosolic frac-
tion of HeLa cells infected with chlamydia (Fig. 3 A, top
row; lane HeLa L2 S100), with a small amount of activity
in the NE fraction (lane HeLa L2 NE). RFX5 degradation
activity correlated very well with the presence of CPAFn
fragment. The cytosolic fraction of uninfected HeLa cells
had no protease activity (lane HeLa S100). Surprisingly, the
purified chlamydial organisms themselves also had no ca-
pacity to degrade RFX5. These findings suggest that CPAF
is mainly localized in the cytosolic fraction of the infected
HeLa cells and does not accumulate to any appreciable ex-
tent in chlamydia organisms themselves.
Figure 3. Intracellular distribution of CPAF
during chlamydial infection. (A) Infected or un-
infected HeLa cells were fractionated into cyto-
solic (S100) and nuclear (NE) fractions as
described in Materials and Methods. The frac-
tionated cellular samples and purified chlamyd-
ial organisms were evaluated for RFX5 degra-
dation activity in a cell-free assay (top row) or
analyzed for the presence of CPAFn (second
row), MOMP (third row), or host heat shock
protein 70 (HSP70; last row) using the corre-
sponding antibodies. HeLa L2 S100 contained
the highest RFX5 degradation activity, with a
small amount of activity detected in the NE
prepared from the same infected cells (lane
HeLa L2 NE). The purified chlamydial organ-
isms in the form of either the infectious ele-
mentary body (lane L2 EB) or the metabolically
active but noninfectious reticulate body (lane
L2 RB) contained no CPAF or CPAF activity.
(B) Immunofluorescence detection of CPAF in
chlamydia-infected cells. HeLa cell monolayer
was infected with chlamydia organisms for 30 h.
The monolayer was costained with Hoechst
32258 for DNA (blue), anti-MOMP antibody
MC22 (probed with an FITC-conjugated,
mouse IgG3-specific secondary antibody;
green), and anti-CPAFn antibody 54b (probed
with a Cy3-conjugated, mouse IgG1-specific
secondary antibody; red). Images were acquired
individually for each stain in gray (top row) us-
ing a Cooker digital camera connected to an
AX70 Olympus microscope and the single-
color images were merged in frame into the tri-
ple-color image (bottom) using the software
Image Pro. Note that the anti-CPAFn antibody
only stained the cytosol (red) of the cells with
chlamydial inclusions (green). 
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An immunofluorescence assay was used to further con-
firm the intracellular distribution of CPAF (Fig. 3 B). CPAF
was only detected in the cells containing chlamydial inclu-
sion bodies but not the adjacent normal HeLa cells growing
on the same coverslip, indicating that CPAF is restricted to
chlamydia-infected cells. As expected from the cell fraction-
ation studies, CPAF was mainly detected in the cytoplasmic
portion of the infected cells, even though CPAF is encoded
by the chlamydial genome. These observations suggest that
the chlamydia-synthesized CPAF is secreted into the host
cell cytoplasm, allowing it to access host proteins.
 
Discussion
 
Chlamydial growth occurs strictly within a modified cy-
toplasmic vacuole of eukaryotic cells (12), and the possibil-
ity of communication between chlamydial vacuoles and
host cellular compartments has frequently been discussed
(13–16). At least one purpose of such transfer of chla-
mydia-derived proteins to the invaded cell appears to be
protection from host immune recognition (4, 5) and attack
(6). Our previous studies suggested that chlamydia may se-
crete a CPAF into the host cell cytosol to degrade tran-
scription factors required for MHC gene activation, thus
limiting expression of these key proteins involved in T cell
antigen recognition (4, 5). We have now identified the
gene encoding CPAF that is secreted into host cell cytosol
and demonstrated that CPAF is both necessary and suffi-
cient for the degradation of the transcription factors RFX5
and USF-1. Interestingly, CPAF was identified as two sep-
arate polypeptides encoded by a single ORF in the
chlamydial genome (Fig. 1 A). Both the CPAFn and
CPAFc fragments are coprecipitated from chlamydia-
infected cell lysates by an antibody that only recognizes the
CPAFn fragment (Fig. 2 C). These observations suggest
that CPAF may function in the form of intramolecular
dimers. Whether CPAF cleavage into CPAFn and CPAFc
is necessary for its degradation activity is not yet known.
Although the details of the activation and secretion of
CPAF remain to be fully determined, it is clear that by se-
creting a single factor into the cytosol, chlamydia can sup-
press both MHC class I and class II antigen expression.
Many viruses are known to cause suppression or degrada-
tion of cellular proteins required for mounting host de-
fense responses (17–19). However, these viral strategies are
often dependent on the function of host proteasomes (20,
21). We have demonstrated that CPAF is both necessary
and sufficient for degrading host transcription factors re-
quired for MHC antigen expression. Thus, this report
identifies a novel molecular mechanism by which a nonvi-
ral intracellular pathogen interacts with its host and manip-
ulates immune responses for its benefit. Further character-
ization of CPAF including its transportation, activation,
and substrate accessibility and selectivity is underway.
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